383 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Is Allergan (AGN) a Great Stock for Value Investors? http://www.zacks.com/stock/news/720736/is-allergan-agn-a-great-stock-for-value-investors?cid=CS-ZC-FT-analyst_blog|value_stocks-720736 Jan 16, 2020 - Let's see if Allergan (AGN) stock is a good choice for value-oriented investors right now from multiple angles.
J&J Seeks Label Expansion for Spravato Nasal Spray in EU http://www.zacks.com/stock/news/720650/jj-seeks-label-expansion-for-spravato-nasal-spray-in-eu?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-720650 Jan 16, 2020 - J&J (JNJ) seeks label expansion for its new nasal spray, Spravato (esketamine), for an expanded patient population in Europe.
3 Large-Cap Dividend Stocks to Buy Now for Your 2020 Portfolio http://www.zacks.com/stock/news/718855/3-large-cap-dividend-stocks-to-buy-now-for-your-2020-portfolio?cid=CS-ZC-FT-stocks_in_the_news|investment_ideas-718855 Jan 15, 2020 - Despite all the positivity, investors should think about adding a few large-cap stocks that pay a solid dividend to help anchor their portfolios in 2020...
Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I http://www.zacks.com/stock/news/716124/aclaris-mk2-inhibitor-shows-encouraging-data-in-phase-i?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-716124 Jan 13, 2020 - Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.
AbbVie Lays Out Plans to Integrate Allergan https://www.fool.com/investing/2020/01/08/abbvie-lays-out-plans-to-integrate-allergan.aspx?source=iedfolrf0000001 Jan 08, 2020 - The company is leaving the aesthetics unit largely intact.
Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101 http://www.zacks.com/stock/news/704735/editas-edit-focuses-on-developing-eye-candidate-edit-101?cid=CS-ZC-FT-analyst_blog|zer_report_update-704735 Jan 06, 2020 - Editas (EDIT) progresses well on developing its lead candidate EDIT-101 to treat LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a concern.
3 Stocks with Solid Entry Points to Consider for 2020 http://www.zacks.com/stock/news/701275/3-stocks-with-solid-entry-points-to-consider-for-2020?cid=CS-ZC-FT-stocks_in_the_news|investment_ideas-701275 Jan 03, 2020 - Geopolitcal headwinds sent stocks lower on Friday as US officials confirmed that President Trump's airstrike killed Iran's top military commander.
Aerie's (AERI) Application for Roclanda Accepted in Europe http://www.zacks.com/stock/news/700586/aeries-aeri-application-for-roclanda-accepted-in-europe?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-700586 Jan 03, 2020 - European authorities accept Aerie's (AERI) filing for its second ophthalmology drug, Roclanda.
3 Dividend-Paying Large Cap Pharma Stocks to Consider for 2020 http://www.zacks.com/stock/news/690807/3-dividend-paying-large-cap-pharma-stocks-to-consider-for-2020?cid=CS-ZC-FT-stocks_in_the_news|investment_ideas-690807 Dec 27, 2019 - The stock market continued its end of the year rally Friday as the three major indices all hit new intraday highs.
Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy http://www.zacks.com/stock/news/685884/allergan-agn-gets-fda-approval-for-migraine-drug-ubrelvy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-685884 Dec 24, 2019 - Allergan (AGN) gets FDA nod for Ubrelvy for the acute treatment of migraine with or without aura in adults.

Pages: 123456...39

Page 1>